<DOC>
	<DOCNO>NCT00664066</DOCNO>
	<brief_summary>This post-authorisation safety study assess incidence severity pre-defined cardiovascular event patient treat DYNEPO , well detect &amp; describe less common adverse drug reaction , summarise DYNEPO drug utilisation .</brief_summary>
	<brief_title>DELFT ( Dynepo Evaluation Long-Term Follow-Up Treatment )</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Adult patient must establish Chronic Kidney Disease ( CKD ) willing able provide write informed consent . Patients must already receive DYNEPO treatment time study entry . Patients likely receive DYNEPO least 1 year . Known intolerance EPO excipients Known suspect Pure Red Cell Aplasia ( PRCA )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>